(NASDAQ: GNLX) Genelux's forecast annual revenue growth rate of 2,630.96% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Genelux's revenue in 2024 is $8,000.On average, 1 Wall Street analysts forecast GNLX's revenue for 2026 to be $1,112,265,688, with the lowest GNLX revenue forecast at $1,112,265,688, and the highest GNLX revenue forecast at $1,112,265,688. On average, 2 Wall Street analysts forecast GNLX's revenue for 2027 to be $2,333,868,173, with the lowest GNLX revenue forecast at $1,889,771,800, and the highest GNLX revenue forecast at $2,777,964,546.
In 2028, GNLX is forecast to generate $4,539,501,831 in revenue, with the lowest revenue forecast at $3,779,543,600 and the highest revenue forecast at $5,299,460,062.